Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

Shinya Goto, Hisao Ogawa, Masaru Takeuchi, Marcus D Flather, Deepak L Bhatt, J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators

Research output: Contribution to journalArticlepeer-review

138 Citations (Scopus)

Abstract

Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).
Original languageEnglish
Pages (from-to)2601-13
Number of pages13
JournalEuropean Heart Journal
Volume31
Issue number21
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Acute Coronary Syndrome
  • Administration, Oral
  • Coronary Artery Disease
  • Double-Blind Method
  • Drug-Induced Liver Injury
  • Female
  • Hemorrhage
  • Humans
  • Imines
  • Long QT Syndrome
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors
  • Pyridines
  • Receptor, PAR-1

Cite this